BusinessAchillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178By Nasdaq OMXApr 22, 2017, 7:00 AM UTC
BusinessAchillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXApr 6, 2017, 10:05 AM UTC
BusinessMYnd Analytics Announces Addition of Donald D’Ambrosio as Chief Financial OfficerBy Nasdaq OMXApr 3, 2017, 12:31 PM UTC
BusinessMYnd Analytics Announces Addition of Donald D’Ambrosio as Chief Financial OfficerBy Nasdaq OMXApr 3, 2017, 12:31 PM UTC
BusinessSummit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMDBy Nasdaq OMXMar 27, 2017, 11:02 AM UTC
BusinessAXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye IndicationsBy Nasdaq OMXMar 21, 2017, 1:01 PM UTC
BusinessAXIM Biotech Retains Ora to Manage Upcoming Product Development and Clinical Trials on Glaucoma and Dry Eye IndicationsBy Nasdaq OMXMar 21, 2017, 1:01 PM UTC
BusinessMYnd Analytics Announces a Strategic One Million Dollar Equity InvestmentBy Nasdaq OMXMar 21, 2017, 12:31 PM UTC
